Clinical trials: Prostatic Disease
Prostate Cancer
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH).
- Trial name
- NCT00444639
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 15 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Ipsen
GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
- Trial name
- NCT01303692
- Where
- 2 sites in South Korea
- Volunteers
- 312 people
- Sponsor
- AstraZeneca
Prostate Cancer
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial to compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in patients with…
- Trial name
- NCT04563936
- Testing
- LY01005 3.6 mg, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Luye Pharma Group Ltd.
Prostate Cancer
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy
- Trial name
- NCT00630799
- Testing
- leuprolide acetate
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- GP-Pharm
Prostate Cancer
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Researchers are seeking better ways to treat men who have non-metastatic castration resistant prostate cancer (nmCRPC). This type of prostate cancer-nmCRPC- is one that has not spread to other parts of the body yet keeps…
- Trial name
- NCT05171387
- Testing
- Darolutamide 600 mg twice daily, Androgen deprivation therapy (ADT)
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Bayer
Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
The purpose of this study is to assess the efficacy and tolerability of zoledronic acid in preventing skeletal-related events in patients with prostate cancer
- Trial name
- NCT00172016
- Testing
- Zoledronic acid
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Benign Prostate Hypertrophy(BPH), Renal Calculi
Stone and Laser Therapies Post-Market Study (SALT)
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g.…
- Conditions
- Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
- Trial name
- SALT (NCT06982235)
- Testing
- Ureteroscope system, Laser system
- Where
- 5 sites in United States
- Volunteers
- 238 people
- Sponsor
- Boston Scientific Corporation
Metastatic Prostate Cancer
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid).
- Trial name
- NCT02962284
- Testing
- abiraterone acetate with Methylprednisolone
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer
Prospective Evaluation of a Commercially Available Hydrogel Spacer
Dosimetry efficacy evaluation of the hydrogel spacer
- Trial name
- BP-008 (NCT05323747)
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioProtect
Urinary Retention
Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
- Trial name
- NCT02643849
- Testing
- The Spanner Temporary Prostatic Stent
- Where
- 6 sites in United States
- Volunteers
- 107 people
- Sponsor
- SRS Medical
Prostate Cancer
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
Two groups of patients with prostate cancer will be enrolled: Group A: patients whose cancer has worsened or spread after being on hormonal therapy and has not had any chemotherapy.
- Trial name
- NCT00557037
- Testing
- Phenoxodiol
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- MEI Pharma, Inc.
Prostatic Neoplasms
Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.
- Trial name
- PROCeed-BR (NCT06457854)
- Where
- 5 sites in Brazil
- Sponsor
- AstraZeneca
Ovarian Cancer, Breast Cancer
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
- Trial name
- NCT05740956
- Testing
- HS-10502
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Prostate Cancer
Vidaza to Restore Hormone Thx Prostate
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of…
- Trial name
- NCT00384839
- Testing
- azacitidine for injectable suspension
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Solid Tumor
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen.
- Trial name
- NCT01234012
- Testing
- IMF-001
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoFrontier, Inc.
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
Febrile Neutropenia, Cancer
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for…
- Conditions
- Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- Monitor-GCSF (NCT01459653)
- Where
- 117 sites in Austria, Belgium and 10 more
- Volunteers
- 1,496 people
- Sponsor
- Sandoz
Prostate Cancer
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.
- Trial name
- CHRONOS3 (NCT02238366)
- Testing
- triptorelin
- Where
- 7 sites in Romania
- Volunteers
- 368 people
- Sponsor
- Ipsen
Prostate Cancer
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored…
- Trial name
- NCT02960022
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- 233 sites in United States, Argentina and 36 more
- Volunteers
- 900 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.